dc.contributor.author | Schaller, UC | |
dc.contributor.author | Michl, G | |
dc.contributor.author | Goebel, FD | |
dc.contributor.author | Klauss, V | |
dc.date.accessioned | 2013-06-18T13:02:47Z | |
dc.date.available | 2013-06-18T13:02:47Z | |
dc.date.issued | 1999 | |
dc.identifier.citation | Ophthalmologe. 1999 Apr;96(4):267-9 | en |
dc.identifier.uri | http://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/10409856 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/35691 | |
dc.description.abstract | BACKGROUND:
Hypopyon-uveitis has been identified as a dosage-dependent side effect in patients with acquired immunodeficiency syndrome who are treated for Mycobacterium avium complex (MAC) infection with systemic rifabutin.
PATIENTS AND METHODS:
We report a 38-year-old female AIDS patient with bilateral hypopyon uveitis under therapy with rifabutin in combination with clarithromycin and indinavir.
RESULTS:
At the time of presentation of the bilateral hypopyon uveitis the patient was treated with rifabutin (300 mg/day), clarithromycin (1000 mg/day) and ethambutol (1000 mg/day) for an M. avium complex infection. Also, the patient received the protease inhibitor indinavir. The rifabutin dose was reduced to 150 mg/day. Hypopyon and inflammation resolved under therapy with steroids.
CONCLUSIONS:
The concomitant use of rifabutin, clarithromycin, and protease inhibitors may lead to hypopyon uveitis. Reduction of dosage of rifabutin (150 mg/day) and treatment with topical steroids are required. | en |
dc.language.iso | en | en |
dc.title | [Acute hypopyon uveitis with rifabutin therapy of systemic Mycobacterium avium complex (MAC) infection in AIDS]. | en |
dc.type | Article | en |
local.publisher | Department of Ophthalmology, College of Health Sciences, University of Nairobi | en |